文献速递前列腺癌

前瞻性适应性效用试验验证尿液外泌体基因表达检测预测初次活检高危前列腺癌

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
PubMed 文献 · Eur Urol · 2018-09-17

一项两阶段适应性临床效用研究(NCT03031418)纳入503例年龄≥50岁、PSA 2-10ng/ml、计划初次前列腺活检的男性,评估ExoDx Prostate(IntelliScore)尿液外泌体基因表达检测区分Grade Group≥2前列腺癌与GG1及良性疾病的表现。EPI的AUC为0.70,优于标准临床参数优化模型的0.62;采用验证切点15.6可避免26%的不必要活检和20%的总活检,NPV 89%,漏诊7%的≥GG2前列腺癌。

要点

  • EPI尿液检测在初次活检人群中区分≥GG2前列腺癌的AUC为0.70,优于标准临床参数模型(AUC 0.62)。
  • 切点15.6可避免26%不必要活检和20%总活检,NPV 89%,漏诊7%的≥GG2前列腺癌。
  • 研究者共识推荐II期使用15.6切点,II期决策影响队列结果将另文报告。

核心结论

  • EPI是一种非侵入、易使用的尿液基因表达检测,已在两项前瞻性验证试验共超过1000例患者中成功验证,可区分≥GG2前列腺癌与GG1及良性疾病。

研究设计与样本

  • 两阶段适应性临床效用研究(NCT03031418),比较EPI结果与活检结局,纳入年龄≥50岁、PSA 2-10ng/ml、计划初次前列腺活检的男性。

主要发现

  • 共503例患者,中位年龄64岁,中位PSA 5.4ng/ml,14%非裔美国人,70%白人,活检阳性率53%(22% GG1、17% GG2、15%≥GG3)。
  • EPI的AUC为0.70,优于标准临床参数优化模型的0.62,与既往发表结果(n=519,EPI AUC 0.71)相当。
  • 验证切点15.6可避免26%的不必要前列腺活检和20%的总活检,NPV 89%,漏诊7%的≥GG2前列腺癌。
  • 替代切点20可避免40%的不必要活检和31%的总活检,NPV 89%,漏诊11%的≥GG2前列腺癌。

关键数值与推荐

  • 临床研究者达成共识,推荐II期使用15.6切点。

临床怎么用

  • 在初次活检决策不确定时,可使用EPI尿液检测辅助风险分层,减少不必要的前列腺活检。

局限性

  • II期决策影响队列的结果将另文报告,本文未报告该队列结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. OBJECTIVE: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy. DESIGN, SETTING, AND PARTICIPANTS: A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2-10ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. RESULTS AND LIMITATIONS: In a total of 503 patients, with median age of 64 yr, median PSA 5.4ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n=519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. CONCLUSIONS: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. PATIENT SUMMARY: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2-10ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. McKiernan J, Donovan MJ, Margolis E, et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol. 2018. PMID: 30237023. doi:10.1016/j.eururo.2018.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。